ClinicalTrials.gg

Program

zenagamtide

Also written as “NNC0487-0111”, “Zenagamtide” and “NNC0487-0111 A”.

In Novo Nordisk's own words, Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Novo Nordisk.

Furthest: phase 3, since Jan 13, 202635 company-led studies, 26 open or runningNext primary completion: Nov 11, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk3526 open or runningphase 3since Jan 13, 2026May 4, 2022Nov 11, 2027phase 1 · NCT07535307
  • Named in Novo Nordisk’s own pipeline as Zenagamtide (sc and oral), phase 3, as of Nov 5, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since May 4, 2022.

  1. Feb 3, 2026Phase 3 study in ObesityNCT07400107 · 985 enrolled · United States, Argentina, Brazil and more
  2. Mar 13, 20263 phase 3 studies in ObesityNCT07481630, NCT07503210, NCT07509307
  3. Mar 27, 2026Phase 1 study in ObesityNCT07508020 · 120 planned · Germany
  4. Apr 9, 2026Phase 1 study in Diabetes MellitusNCT07535307 · 80 planned · Germany
  5. Apr 9, 20264 phase 3 studiesNCT07533175, NCT07567001, NCT07571109 and 1 more
  6. May 8, 2026Phase 1 study in OverweightNCT07587710 · 35 planned · Slovakia
  7. Jun 18, 20262 phase 3 studiesNCT07668401, NCT07668414
  8. Jul 17, 2026Phase 3 study in OverweightNCT07720271 · 950 planned · United States
  9. Jul 30, 2026Phase 1 study in OverweightNCT07757087 · 120 planned · Denmark, Netherlands
  10. Aug 26, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07797335 · 1,778 planned · United States, Argentina, Brazil and more
  11. Sep 6, 20262 phase 1 studies in OverweightNCT07815067, NCT07855133
  12. Sep 10, 20262 phase 3 studiesNCT07822061, NCT07861100
  13. Oct 5, 2026Phase 1 study in OverweightNCT07868354 · 60 planned · United States
  14. Nov 6, 20264 phase 3 studies in Diabetes Mellitus, Type 2NCT07931599, NCT07931573, NCT07931547 and 1 more

Ahead

  1. Nov 11, 2027Primary completion: phase 1 study in Diabetes MellitusNCT07535307
  2. Dec 1, 2027Primary completion: phase 1 study in OverweightNCT07587710
  3. Jan 19, 2028Primary completion: phase 1 study in ObesityNCT07508020
  4. Jun 5, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07931495

TargetBeta

“Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.”company, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
CagriSema ANovo Nordiskphase 11

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07931599Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3Not yet recruitingJul 24, 20281,060
NCT07931573Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3Not yet recruitingJul 4, 20281,200
NCT07931547Diabetes Mellitus, Type 2 · United States, Brazil, China and more3Not yet recruitingJul 31, 2028450
NCT07931495Diabetes Mellitus, Type 2 · United States, China, Japan and more3Not yet recruitingJun 5, 2028200
NCT07868354Overweight · United States1RecruitingSep 7, 202860
NCT07861100Obesity · United States, Argentina, Australia and more3Not yet recruitingSep 16, 20308,500
NCT07855133Overweight · United States1RecruitingSep 6, 202860
NCT07822061Overweight · Japan3RecruitingFeb 5, 2029400
NCT07815067Overweight · Germany1RecruitingJun 12, 2028320
NCT07797335Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3RecruitingJul 31, 20281,778
NCT07757087Overweight · Denmark, Netherlands1RecruitingSep 18, 2028120
NCT07720271Overweight · United States3RecruitingJun 27, 2028950
NCT07668414Overweight · United States3RecruitingOct 10, 2028650
NCT07668401Obesity · India, Japan, Malaysia and more3Not yet recruitingJan 11, 2029400
NCT07587710Overweight · Slovakia1RecruitingDec 1, 202735
NCT07571109Obesity · United States, Australia, China and more3RecruitingJun 26, 2028300
NCT07571005Obesity · United States, Australia, China and more3RecruitingJul 12, 2028300
NCT07567001Obesity · United States, Argentina, Australia and more3RecruitingJul 23, 20295,610
NCT07535307Diabetes Mellitus · Germany1RecruitingNov 11, 202780
NCT07533175Diabetes Mellitus · United States, Argentina, Brazil and more3Active, not recruitingAug 7, 2028638
NCT07509307Obesity · United States, Australia, Bulgaria and more3RecruitingAug 14, 2028400
NCT07508020Obesity · Germany1RecruitingJan 19, 2028120
NCT07503210Obesity · United States, Argentina, Australia and more3Active, not recruitingJun 6, 2028606
NCT07481630Obesity · United States, Australia, Bulgaria and more3RecruitingAug 14, 2028400
NCT07400107Obesity · United States, Argentina, Brazil and more3Active, not recruitingDec 19, 2028985
NCT07339423Obesity · United States, Argentina, Australia and more3RecruitingJun 26, 20291,150
NCT07121153Overweight · China1CompletedDec 20, 202536
NCT06820476Overweight · China1CompletedMay 14, 202529
NCT06559527Diabetes Mellitus, Type 2 · Germany1CompletedFeb 24, 202542
NCT06542874Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more2CompletedOct 1, 2025448
NCT06478563Obesity · United States1CompletedJun 5, 2025133
NCT06461039Obesity · Canada1CompletedMar 16, 202543
NCT06064006Obesity · United States2CompletedNov 27, 2024125
NCT06049329Obesity · Japan1CompletedDec 15, 202336
NCT05369390Obesity · United States1CompletedJan 9, 2024144

How it is read

Names in the registry

  • “NNC0487-0111”, 18 entries
  • “Zenagamtide”, 10 entries
  • “NNC0487-0111 A”, 3 entries
  • “Zenagamtide injection”, 1 entry
  • “Zenagamtide tablet”, 1 entry

Codes read as this program: NNC04870111.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.